NEWS & VIEWS THERAPY
Antiphospholipid syndrome research needs more collaboration Doruk Erkan and Michael D. Lockshin
Pathogenesis, treatment options and outcomes for antiphospholipid syndrome (APS) are poorly defined. A new observational collaborative study has analysed morbidity and mortality in APS, but, ultimately, the data that will guide us to optimally treat patients with APS are lacking. Here we provide a construct for future large-scale collaborative studies. Erkan, D. & Lockshin, M. D. Nat. Rev. Rheumatol. 10, 266–267 (2014); published online 11 March 2014; doi:10.1038/nrrheum.2014.39
The Euro-Phospholipid Project Group (EPPG) has now published prospective 10year outcome data from 1,000 patients with antiphospholipid syndrome (APS) who were studied between 1999 and 2009.1 This new APS study is not the first long-term outcome data, but prior studies were smal ler, of shorter duration or limited to single manifestations of APS.2,3 Cervera et al.1 reported high 10‑year survival probability (90.7%) and low complication rates (
Antiphospholipid syndrome research needs more collaboration Doruk Erkan and Michael D. Lockshin
Pathogenesis, treatment options and outcomes for antiphospholipid syndrome (APS) are poorly defined. A new observational collaborative study has analysed morbidity and mortality in APS, but, ultimately, the data that will guide us to optimally treat patients with APS are lacking. Here we provide a construct for future large-scale collaborative studies. Erkan, D. & Lockshin, M. D. Nat. Rev. Rheumatol. 10, 266–267 (2014); published online 11 March 2014; doi:10.1038/nrrheum.2014.39
The Euro-Phospholipid Project Group (EPPG) has now published prospective 10year outcome data from 1,000 patients with antiphospholipid syndrome (APS) who were studied between 1999 and 2009.1 This new APS study is not the first long-term outcome data, but prior studies were smal ler, of shorter duration or limited to single manifestations of APS.2,3 Cervera et al.1 reported high 10‑year survival probability (90.7%) and low complication rates (
